ProtoKinetix First in Series of Town Hall Shareholder Meetings
May 30, 2019MARIETTA, Ohio–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AAGP?src=hash" target="_blank"gt;#AAGPlt;/agt;–ProtoKinetix, Incorporated (www.protokinetix.com)
(the “Company” or “ProtoKinetix”) (OTCQB:PKTX)
today announces that it will hold the first in a series of Town
Hall Meetings. This meeting is being held to update shareholders
on the current status of the company’s ongoing research projects. In
addition, we will be outlining our vision of the way forward and
reviewing some exciting new projects under consideration.
The first two of these meetings have been scheduled for:
-
Sunday, June 9, from 2:00 PM to 4:00 PM, at The Parkersburg Country
Club located at 4910 1st Ave. Vienna, WV 26105.
Appetizers and refreshments provided. -
Monday, June 10, from 5:00 PM to 7:00 PM, at The Buckhead Club
located at 3344 Peachtree Road Suite 2600 Atlanta, GA 30326.
Appetizers and refreshments provided.
We look forward to meeting you and your guest. Please feel free to
contact me if you have any questions concerning this event. RSVP via
email is appreciated ([email protected]).
About ProtoKinetix, Incorporated
ProtoKinetix is a molecular biotechnology company that has developed and
patented a family of hyper stable, potent glycopeptides (AAGP®) that
enhance both engraftment and protection of transplanted cells used in
regenerative medicine. Due to the results achieved over the last four
years of testing, the University of Alberta has begun Phase 1 human
clinical trials. Additional studies will be expanded to include whole
organ transplantation and all therapies that are being developed
globally to date; diabetes, retinal degeneration, cardiac repair and
many other degenerative conditions. In addition, we are studying the
potential impact on several cancer therapies.
For more Company information and to join our email listing visit our
website at ProtoKinetix.com.
Cautionary Note Regarding Forward-Looking Statements
The information discussed in this press release includes “forward
looking statements” within the meaning of Section 27A of the Securities
Act of 1933 (the “Securities Act”) and Section 21E of the Securities
Exchange Act of 1934 (the “Exchange Act”). All statements, other
than statements of historical facts, included herein concerning, among
other things, planned capital expenditures, future cash flows and
borrowings, pursuit of potential acquisition opportunities, our
financial position, business strategy and other plans and objectives for
future operations, are forward looking statements. These forward looking
statements are identified by their use of terms and phrases such as
“may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,”
“achievable,” “anticipate,” “will,” “continue,” “potential,” “should,”
“could,” and similar terms and phrases. Although we believe that
the expectations reflected in these forward looking statements are
reasonable, they do involve certain assumptions, risks and uncertainties
and are not (and should not be considered to be) guarantees of future
performance. Among these risks are those set forth in a Form 10-K
filed on March 12, 2019. It is important that each person reviewing this
release understand the significant risks attendant to the operations of
ProtoKinetix. ProtoKinetix disclaims any obligation to update any
forward-looking statement made here.
This press release does not constitute or form a part of any offer or
solicitation to purchase or subscribe for securities in the United
States. The securities referred to herein have not been and will not be
registered under the Securities Act of 1933, as amended (the “Securities
Act”), or with any securities regulatory authority of any state or other
jurisdiction in the United States, and may not be offered or sold,
directly or indirectly, except pursuant to an exemption from or in a
transaction not subject to the registration requirements of the
Securities Act.
Contacts
Clarence E. Smith
President and Chief Executive Officer
Telephone:
304-299-5070
Email: [email protected]
Twitter:
@ProtoKinetix